Teratogenicity Assessment Protocol

Teratogenicity assessment protocol evaluates developmental harm potential from embryonic pharmaceutical exposure. Animal testing across critical developmental windows predicts human risk. Structural alerts identify likely teratogens. Mechanism understanding enables risk stratification. Regulatory categorisation communicates fetal risk.

Clinical monitoring detects unexpected developmental effects. Pregnancy registries track exposed pregnancies. Healthcare provider communication emphasises risks. Regulatory submissions address teratogenicity findings. Post-approval surveillance identifies unexpected effects.